This clinical study is designed to evaluate the safety and effectiveness of the subcutaneous implantable defibrillator (S-ICD) System.
This clinical study is a prospective, non-randomized, multicenter clinical study without a control group conducted in the United States, Europe, and New Zealand. Patients meeting eligibility criteria for implanting an S-ICD System will be enrolled in this clinical study, implanted with an S-ICD System, and followed prior to hospital discharge, and post-implant at 30 days, 90 days, and 180 days. After the 180-day post-implant follow-up visit, patients will continue to be followed semi-annually until study closure. Eligible patients enrolled in this clinical study may also participate in the chronic conversion sub-study. The safety endpoint will be evaluated through the use of a 180-day S-ICD System complication-free rate. The effectiveness endpoint will be evaluated using an induced ventricular fibrillation (VF) conversion efficacy rate. Spontaneous episodes and chronic conversion testing data will be evaluated using descriptive statistics to provide additional data supporting the continued chronic performance of the S-ICD System.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
330
The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
Percentage of Participants Free of Type I Complications at 180 Days.
Percentage of Participants Free of Type I Complications at 180 days compared to the performance goal of 79%. Type I complications are those caused by the S-ICD System.
Time frame: 180 days
Percentage of Participants Who Pass Induced VF Conversion Test
Percentage of participants who pass induced VF conversion test was compared to a performance goal of 88%. Definition of a success was two consecutive successful 65 joule shocks out of four attempts in the same polarity.
Time frame: Implant/Pre-Discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Arizona Arrhythmia Consultants
Scottsdale, Arizona, United States
University of Southern California
Los Angeles, California, United States
Foothill Cardiology
Pasadena, California, United States
CMCA / Sequoia Hospital
Redwood City, California, United States
Sharp Grossmont Hospital
San Diego, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Pacific Heart Institute
Santa Monica, California, United States
South Bay Electrophysiology
Torrance, California, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Emory University School of Medicine
Atlanta, Georgia, United States
...and 23 more locations